CR11863A - Composiciones y metodos para anticuerpos terapeuticos - Google Patents

Composiciones y metodos para anticuerpos terapeuticos

Info

Publication number
CR11863A
CR11863A CR11863A CR11863A CR11863A CR 11863 A CR11863 A CR 11863A CR 11863 A CR11863 A CR 11863A CR 11863 A CR11863 A CR 11863A CR 11863 A CR11863 A CR 11863A
Authority
CR
Costa Rica
Prior art keywords
antibodies
compositions
methods
therapeutic antibodies
baffr
Prior art date
Application number
CR11863A
Other languages
English (en)
Inventor
Heusser Christoph
Neugebauer Julia
Schaadt Eveline
Urlinger Stefanie
Woisetschlaeger Maximilian
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11863(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR11863A publication Critical patent/CR11863A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos que se enlazan específicamente al receptor de BAFF (BAFFR). De una manera más específica, anticuerpos que son antagonistas del BAFFR, con actividad consumidora de células-B in vivo, y composiciones y métodos de uso para estos anticuerpos con el fin de tratar los trastornos patológicos que puedan ser tratados mediante la aniquilación o el consumo de las células-B, tales como lupus eritematoso sistémico o artritis reumatoide, u otras enfermedades autoinmunes o linfomas, leucemias, y mielomas.
CR11863A 2008-07-17 2010-12-21 Composiciones y metodos para anticuerpos terapeuticos CR11863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15

Publications (1)

Publication Number Publication Date
CR11863A true CR11863A (es) 2011-02-11

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11863A CR11863A (es) 2008-07-17 2010-12-21 Composiciones y metodos para anticuerpos terapeuticos

Country Status (40)

Country Link
US (3) US8106163B2 (es)
EP (1) EP2315780B8 (es)
JP (2) JP5767109B2 (es)
KR (2) KR101314369B1 (es)
CN (1) CN102119174B (es)
AR (1) AR072749A1 (es)
AU (1) AU2009272771B2 (es)
BR (1) BRPI0915928B8 (es)
CA (1) CA2730063C (es)
CL (1) CL2011000086A1 (es)
CR (1) CR11863A (es)
CU (1) CU23878B1 (es)
CY (1) CY1116800T1 (es)
DK (1) DK2315780T3 (es)
DO (1) DOP2011000016A (es)
EA (1) EA024492B1 (es)
EC (1) ECSP11010761A (es)
ES (1) ES2547270T3 (es)
GE (1) GEP20146129B (es)
HR (1) HRP20151227T1 (es)
HU (1) HUE025778T2 (es)
IL (1) IL210485A (es)
JO (1) JO3149B1 (es)
MA (1) MA32481B1 (es)
MX (1) MX2011000616A (es)
MY (1) MY158980A (es)
NI (1) NI201100017A (es)
NZ (1) NZ590057A (es)
PE (1) PE20110563A1 (es)
PL (1) PL2315780T3 (es)
PT (1) PT2315780E (es)
RS (1) RS54299B1 (es)
SG (1) SG193805A1 (es)
SI (1) SI2315780T1 (es)
SM (1) SMP201100010B (es)
SV (1) SV2011003807A (es)
TW (1) TWI508742B (es)
UY (1) UY31987A (es)
WO (1) WO2010007082A1 (es)
ZA (1) ZA201008952B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222846B1 (en) * 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
HUE028603T2 (en) * 2011-05-13 2016-12-28 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
JP7132123B2 (ja) 2016-02-10 2022-09-06 ノバルティス アーゲー 原発性シェーグレン症候群の治療のためのｐｉ３ｋの活性阻害剤または機能阻害剤の使用
EP3464374B1 (en) * 2016-06-06 2025-08-06 City of Hope Baff-r antibodies and uses thereof
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
MA50435A (fr) * 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
SG11202011597RA (en) * 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
MX2021011464A (es) * 2019-03-29 2021-10-22 Chugai Pharmaceutical Co Ltd Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
EP4055047A1 (en) * 2019-11-06 2022-09-14 Novartis AG Treatment for sjögren's syndrome
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN116096414A (zh) * 2020-08-04 2023-05-09 诺华股份有限公司 Cll的治疗
WO2022031567A1 (en) 2020-08-04 2022-02-10 Novartis Ag Treatment of b cell malignancies
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
WO2022097061A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
EP4334351A1 (en) 2021-05-04 2024-03-13 Novartis AG Treatment for systemic lupus erythematosus using anti-baffr antibodies
CN117203240A (zh) 2021-05-04 2023-12-08 诺华股份有限公司 使用抗baffr抗体治疗狼疮肾炎
CA3233246A1 (en) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Antibodies targeting baff-r and use thereof
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
WO2025058962A1 (en) * 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en) 2023-12-19 2025-06-26 Basf Se Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090016772A (ko) * 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
IL210485A (en) 2015-03-31
BRPI0915928B1 (pt) 2020-10-20
JP5767109B2 (ja) 2015-08-19
US8106163B2 (en) 2012-01-31
ZA201008952B (en) 2012-01-25
KR101314369B1 (ko) 2013-10-10
RS54299B1 (sr) 2016-02-29
JP2015133983A (ja) 2015-07-27
CY1116800T1 (el) 2017-03-15
PE20110563A1 (es) 2011-08-29
CU23878B1 (es) 2013-04-19
HK1150839A1 (en) 2012-01-13
CA2730063A1 (en) 2010-01-21
NI201100017A (es) 2012-08-17
TW201006493A (en) 2010-02-16
BRPI0915928A2 (pt) 2015-11-03
SI2315780T1 (sl) 2015-11-30
BRPI0915928B8 (pt) 2021-05-25
SMP201100010B (it) 2011-09-09
ECSP11010761A (es) 2011-02-28
WO2010007082A1 (en) 2010-01-21
KR20110020914A (ko) 2011-03-03
CA2730063C (en) 2017-04-18
CL2011000086A1 (es) 2011-07-01
TWI508742B (zh) 2015-11-21
PL2315780T3 (pl) 2016-01-29
CU20110013A7 (es) 2012-06-21
JO3149B1 (ar) 2017-09-20
EP2315780B1 (en) 2015-08-19
JP2011527896A (ja) 2011-11-10
IL210485A0 (en) 2011-03-31
EA201100191A1 (ru) 2011-08-30
US9382326B2 (en) 2016-07-05
SV2011003807A (es) 2011-03-23
JP6077587B2 (ja) 2017-02-08
US20120195913A1 (en) 2012-08-02
MX2011000616A (es) 2011-02-24
AU2009272771A1 (en) 2010-01-21
SG193805A1 (en) 2013-10-30
KR101545795B1 (ko) 2015-08-19
MA32481B1 (fr) 2011-07-03
ES2547270T3 (es) 2015-10-05
UY31987A (es) 2010-02-26
GEP20146129B (en) 2014-08-11
NZ590057A (en) 2012-08-31
PT2315780E (pt) 2015-11-30
CN102119174B (zh) 2015-01-21
EA024492B1 (ru) 2016-09-30
EP2315780A1 (en) 2011-05-04
HRP20151227T1 (hr) 2015-12-18
AU2009272771B2 (en) 2012-09-20
HUE025778T2 (en) 2016-05-30
US9340620B2 (en) 2016-05-17
DOP2011000016A (es) 2011-02-15
US20100021452A1 (en) 2010-01-28
MY158980A (en) 2016-11-30
CN102119174A (zh) 2011-07-06
EP2315780B8 (en) 2015-09-23
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
DK2315780T3 (en) 2015-10-19
KR20130098432A (ko) 2013-09-04
AR072749A1 (es) 2010-09-15

Similar Documents

Publication Publication Date Title
CR11863A (es) Composiciones y metodos para anticuerpos terapeuticos
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
DOP2013000260A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
CO6541572A2 (es) Octahidropirrolo[3.4-c]pirrolos distituidos como moduladores del receptor de orexina
UY33651A (es) Anticuerpos anti-il12rbeta1 y su uso para tratar los trastornos autoinmunes e inflamatorios
CL2008001335A1 (es) Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
AR054539A1 (es) Nuevos anticuerpos anti- madcam
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
MX2009006786A (es) Composiciones y metodos para el tratamiento de infecciones y tumores.
EA201300730A1 (ru) Производные индазолилтриазола
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
MX2014008773A (es) Composiciones y metodos para el uso de ésteres de forbol.
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
EA201101572A1 (ru) Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2013003125A1 (es) Compuestos derivados de isoxazolinas inhibidores mps; composicion farmaceutica que los comprende; kit farmaceutico; y uso en el tratamiento de una enfermedad tales como osteoartritis, artritis reumatoide, artritis juvenil, artritis psoriasica, lupus eritematoso sistemico, entre otras.